Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22528183 | 0.83 | LMNA (0.42) | LMNAMAP3K14KDM4EBLMMEN1 | |
| SCHEMBL27873870 | 0.81 | LMNA (0.45) | LMNAMAP3K14KDM4EBLMMEN1 | |
| SCHEMBL30034979 | 0.79 | NOTUM (0.41) | LMNAMAP3K14KDM4EBLMGAA | |
| SCHEMBL5653476 | 0.78 | LMNA (0.43) | LMNAMAP3K14KDM4EBLMMEN1 | |
| SCHEMBL4427821 | 0.75 | LMNA (0.53) | LMNAMAP3K14KDM4EMEN1KMT2A | |
| SCHEMBL29102668 | 0.72 | LMNA (0.50) | LMNAMAP3K14KDM4EMEN1KMT2A | |
| SCHEMBL30034849 | 0.72 | LMNA (0.39) | LMNAMAP3K14KDM4EBLMPARP1 | |
| SCHEMBL308631 | 0.70 | — | — | |
| SCHEMBL10877381 | 0.69 | CES1 (0.42) | LMNAKDM4EBLMOPRM1CYP11B1 | |
| SCHEMBL27829931 | 0.69 | LMNA (0.44) | LMNAMAP3K14KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | LMNA 4648/4885MAP3K14 2246/4885KDM4E 141/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | LMNA 4437/4885MAP3K14 3448/4885KDM4E 137/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | LMNA 4418/4885MAP3K14 3435/4885KDM4E 139/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | LMNA 4699/4885MAP3K14 3538/4885KDM4E 233/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | LMNA 4448/4885MAP3K14 3431/4885KDM4E 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.